PD-1xVEGF bispecific antibodies Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:46
Jan 15
Jan 15
PD-1xVEGF bispecifics are major post-Keytruda trend.
PD-1xVEGF bispecific antibodies are the closest and most active post-Keytruda trend, with large pharma upfront deals and clinical data showing improved progression-free survival versus Keytruda, though efficacy limitations remain. He sees the area as a major deal-making theme to monitor.
MED
About PD-1xVEGF bispecific antibodies Investor Commentary
Across the available history and selected sources, Buzzberg tracks PD-1xVEGF bispecific antibodies across 1 sources: 0 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Yoon Ju-han.